Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

Subodh K. Samrat, Jimin Xu, Zhong Li, Jia Zhou, Hongmin Li

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Flaviviruses cause a significant amount of mortality and morbidity, especially in regions where they are endemic. A recent example is the outbreak of Zika virus throughout the world. Development of antiviral drugs against different viral targets is as important as the development of vaccines. During viral replication, a single polyprotein precursor (PP) is produced and further cleaved into individual proteins by a viral NS2B-NS3 protease complex together with host proteases. Flavivirus protease is one of the most attractive targets for development of therapeutic antivirals because it is essential for viral PP processing, leading to active viral proteins. In this review, we have summarized recent development in drug discovery targeting the NS2B-NS3 protease of flaviviruses, especially Zika, dengue, and West Nile viruses.

Original languageEnglish (US)
Article number293
Issue number3
StatePublished - Mar 2022


  • Dengue virus
  • Flavivirus
  • Inhibitors
  • NS2B-NS3
  • West Nile virus
  • Zika virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Biology
  • General Immunology and Microbiology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Antiviral Agents against Flavivirus Protease: Prospect and Future Direction'. Together they form a unique fingerprint.

Cite this